 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H30N4O2 |
| Molar mass | 370.497 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADB-CHMINACA (also known asADMB-CHMINACA[3] andMAB-CHMINACA) is anindazole-basedsynthetic cannabinoid. It is a potentagonist of theCB1 receptor with a binding affinity ofKi = 0.289 nM and was originally developed byPfizer in 2009 as ananalgesic medication.[4][5] It was identified in cannabinoid blends in Japan in early 2015.[6]
There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.[7][8][9][10][11][12][13][14]
In the United States, ADB-CHMINACA is aSchedule I controlled substance.[15] Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014.[16]
Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014.[17]
ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[18]
ADB-CHMINACA is illegal in Switzerland as of December 2015.[19]
Ten ADB-CHMINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Most transformations occurred at the cyclohexylmethyl tail of the compound.[20]
